Let's remember...
The below and most-recent announcements...
Most recent:
http://bgmedtech.com/bud-genius-announces-int...ny-shares/
Previous:
http://www.marketwatch.com/story/buyback-comp...2014-09-18
Buyback Completed as Promised: Bud Genius Announces New Lower Outstanding and Authorized Shares - More Buybacks Planned
Published: Sept 18, 2014 8:37 a.m. ET
LOS ANGELES, Sep 18, 2014 (BUSINESS WIRE) -- The directors of Rightsmile, Inc., also known as Bud Genius, Inc., have successfully completed a reduction of nearly 5% of the outstanding and authorized shares of the company’s common stock. Following the completion of a share buyback, the board passed a resolution to lower the authorized shares of the company's common stock by 4.99% following a stock buyback, which was confirmed by the stock transfer agent yesterday. The company will continue its repurchase efforts.
CEO Angel Stanz had this to say: “In the past we had to do some drastic things to secure our funding, but now we are in a much better position and we can use our new subsidiary to leverage our stock. I want to buy more. The outstanding shares of the company are too high, we will continue to work on it, and we will continue to lower the authorized shares every time we make progress. We have a lot more to do, and I intend to take advantage of the opportunity now to buy our stock back at a strong price advantage.”
Copies of the completed resolution have been received by the Transfer Agent and have been sent to OTC Markets for reporting. The updates will be recorded at the state following the completion of other pending stock buybacks and will be shown in the company’s SEC filings in the next quarterly report.
About Bud Genius
An early leader in an industry that many are speculating will grow, Bud Genius is one of the first established analytical cannabis laboratories in the United States. Bud Genius was launched to bring vendors together with doctors, patients, and dispensaries that require certified products held to demanding standards. Bud Genius has a vision to expand across the US and abroad serving as the beacon of quality for medical cannabis and adult-use marijuana through the formation of regional laboratories. Certification, data collection, and online reports are the measure by which the company gains.
For more information please visit:
http://www.BudGenius.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE: Bud Genius
Bud Genius
Angel Stanz, 855-723-3283
Chief Executive Officer
PR@BudGenius.com
Copyright Business Wire 2014
LOS ANGELES --(BUSINESS WIRE)-- The directors of Rightsmile, Inc. , also known as Bud Genius, Inc. , have successfully completed a reduction of nearly 5% of the outstanding and authorized shares of the company's common stock. Following the completion of a share buyback, the board passed a resolution to lower the authorized shares of the company's common stock by 4.99% following a stock buyback, which was confirmed by the stock transfer agent yesterday. The company will continue its repurchase efforts.
CEO Angel Stanz had this to say: "In the past we had to do some drastic things to secure our funding, but now we are in a much better position and we can use our new subsidiary to leverage our stock. I want to buy more. The outstanding shares of the company are too high, we will continue to work on it, and we will continue to lower the authorized shares every time we make progress. We have a lot more to do, and I intend to take advantage of the opportunity now to buy our stock back at a strong price advantage."
Copies of the completed resolution have been received by the Transfer Agent and have been sent to OTC Markets for reporting. The updates will be recorded at the state following the completion of other pending stock buybacks and will be shown in the company's SEC filings in the next quarterly report.
About Bud Genius
An early leader in an industry that many are speculating will grow, Bud Genius is one of the first established analytical cannabis laboratories in the United States . Bud Genius was launched to bring vendors together with doctors, patients, and dispensaries that require certified products held to demanding standards. Bud Genius has a vision to expand across the US and abroad serving as the beacon of quality for medical cannabis and adult-use marijuana through the formation of regional laboratories. Certification, data collection, and online reports are the measure by which the company gains.
For more information please visit: http://www.BudGenius.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
The below and most-recent announcements...
Most recent:
http://bgmedtech.com/bud-genius-announces-int...ny-shares/
Previous:
http://www.marketwatch.com/story/buyback-comp...2014-09-18
Buyback Completed as Promised: Bud Genius Announces New Lower Outstanding and Authorized Shares - More Buybacks Planned
Published: Sept 18, 2014 8:37 a.m. ET
LOS ANGELES, Sep 18, 2014 (BUSINESS WIRE) -- The directors of Rightsmile, Inc., also known as Bud Genius, Inc., have successfully completed a reduction of nearly 5% of the outstanding and authorized shares of the company’s common stock. Following the completion of a share buyback, the board passed a resolution to lower the authorized shares of the company's common stock by 4.99% following a stock buyback, which was confirmed by the stock transfer agent yesterday. The company will continue its repurchase efforts.
CEO Angel Stanz had this to say: “In the past we had to do some drastic things to secure our funding, but now we are in a much better position and we can use our new subsidiary to leverage our stock. I want to buy more. The outstanding shares of the company are too high, we will continue to work on it, and we will continue to lower the authorized shares every time we make progress. We have a lot more to do, and I intend to take advantage of the opportunity now to buy our stock back at a strong price advantage.”
Copies of the completed resolution have been received by the Transfer Agent and have been sent to OTC Markets for reporting. The updates will be recorded at the state following the completion of other pending stock buybacks and will be shown in the company’s SEC filings in the next quarterly report.
About Bud Genius
An early leader in an industry that many are speculating will grow, Bud Genius is one of the first established analytical cannabis laboratories in the United States. Bud Genius was launched to bring vendors together with doctors, patients, and dispensaries that require certified products held to demanding standards. Bud Genius has a vision to expand across the US and abroad serving as the beacon of quality for medical cannabis and adult-use marijuana through the formation of regional laboratories. Certification, data collection, and online reports are the measure by which the company gains.
For more information please visit:
http://www.BudGenius.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE: Bud Genius
Bud Genius
Angel Stanz, 855-723-3283
Chief Executive Officer
PR@BudGenius.com
Copyright Business Wire 2014
LOS ANGELES --(BUSINESS WIRE)-- The directors of Rightsmile, Inc. , also known as Bud Genius, Inc. , have successfully completed a reduction of nearly 5% of the outstanding and authorized shares of the company's common stock. Following the completion of a share buyback, the board passed a resolution to lower the authorized shares of the company's common stock by 4.99% following a stock buyback, which was confirmed by the stock transfer agent yesterday. The company will continue its repurchase efforts.
CEO Angel Stanz had this to say: "In the past we had to do some drastic things to secure our funding, but now we are in a much better position and we can use our new subsidiary to leverage our stock. I want to buy more. The outstanding shares of the company are too high, we will continue to work on it, and we will continue to lower the authorized shares every time we make progress. We have a lot more to do, and I intend to take advantage of the opportunity now to buy our stock back at a strong price advantage."
Copies of the completed resolution have been received by the Transfer Agent and have been sent to OTC Markets for reporting. The updates will be recorded at the state following the completion of other pending stock buybacks and will be shown in the company's SEC filings in the next quarterly report.
About Bud Genius
An early leader in an industry that many are speculating will grow, Bud Genius is one of the first established analytical cannabis laboratories in the United States . Bud Genius was launched to bring vendors together with doctors, patients, and dispensaries that require certified products held to demanding standards. Bud Genius has a vision to expand across the US and abroad serving as the beacon of quality for medical cannabis and adult-use marijuana through the formation of regional laboratories. Certification, data collection, and online reports are the measure by which the company gains.
For more information please visit: http://www.BudGenius.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
